Related Experiment Video

Updated: Aug 8, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells

Joseph N Contessa1, Angela Abell, Kristoffer Valerie

  • 1Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond VA, USA. jcontess@med.umich.edu

International Journal of Radiation Oncology, Biology, Physics
|June 6, 2006
PubMed
Abstract

Insights

The epidermal growth factor receptor mutant EGFR-CD533 enhances radiosensitization in carcinoma cells by blocking the ErbB receptor tyrosine kinase network. This mechanism is effective regardless of initial receptor expression levels, offering a broad therapeutic advantage.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Epidermal growth factor receptor (EGFR) plays a key role in cancer cell proliferation.
  • EGFR-CD533 is a deletion mutant of EGFR that has shown radiosensitizing properties.
  • Understanding the mechanism of EGFR-CD533 is crucial for its therapeutic application.

Purpose of the Study:

  • To investigate the effects of EGFR-CD533 on other ErbB receptor tyrosine kinase (RTK) family members.
  • To elucidate the mechanism of EGFR-CD533-mediated radiosensitization.
  • To quantify the impact of EGFR-CD533 on cancer cell signaling pathways.

Main Methods:

  • Adenoviral transduction of breast carcinoma cell lines with EGFR-CD533 and ErbB2-CD572 deletion mutants.
  • Assessment of ErbB RTK activation and downstream signaling (MAPK, PI3K/p70S6K).
  • Evaluation of clonogenic survival and cellular radiation damage repair.

Main Results:

  • EGFR-CD533 expression radiosensitized carcinoma cells with varying EGFR levels by blocking the ErbB RTK network.
  • Significant enhancement of alpha/beta ratios was observed, indicating increased radiation sensitivity.
  • EGFR-CD533 reduced the repair of cellular damage post-ionizing radiation.

Conclusions:

  • EGFR-CD533 inhibits the ErbB RTK network, leading to radiosensitization of carcinoma cells irrespective of ErbB RTK expression patterns.
  • ErbB2-CD572 did not exhibit radiosensitizing effects in cells with low EGFR expression.
  • EGFR-CD533's mechanism involves ErbB RTK network inhibition, offering a potential advantage for radiosensitizing diverse malignant cell types.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...